Response failure to the treatment of Clostridium difficile infection and its impact on 30-day mortality

Hepato-Gastroenterology

Volumn 60, Issue 123, 2013, Pages 543-548

  Kim, Eun Soo ^a   Kim, Yong Jin ^a   Park, Chang Wook ^a   Cho, Kwang Bum ^a   Jang, Byoung Kuk ^a   Chung, Woo Jin ^a   Hwang, Jae Seok ^a   Park, Kyung Sik ^a  

^a Keimyung University School of Medicine   (South Korea)

Author keywords

Clostridium difficile infection; Mortality; Response failure

Indexed keywords

ALBUMIN; AMINOGLYCOSIDE; CEPHALOSPORIN; CLINDAMYCIN; METRONIDAZOLE; QUINOLONE; VANCOMYCIN;

ADULT; AGED; ANTIBIOTIC THERAPY; ARTICLE; CLOSTRIDIUM DIFFICILE; CLOSTRIDIUM INFECTION; CONTROLLED STUDY; DIARRHEA; DISEASE ASSOCIATION; DISEASE SEVERITY; DRUG TREATMENT FAILURE; FEMALE; GASTROINTESTINAL ENDOSCOPY; HOSPITAL ADMISSION; HUMAN; INTENSIVE CARE UNIT; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; MORTALITY; OBSERVATIONAL STUDY; PRIORITY JOURNAL; PSEUDOMEMBRANOUS COLITIS; RETROSPECTIVE STUDY; RISK FACTOR; SEPSIS; TREATMENT RESPONSE;

AGED; ANTI-BACTERIAL AGENTS; CHI-SQUARE DISTRIBUTION; CLOSTRIDIUM DIFFICILE; ENDOSCOPY, GASTROINTESTINAL; ENTEROCOLITIS, PSEUDOMEMBRANOUS; FECES; FEMALE; HOSPITAL MORTALITY; HUMANS; LOGISTIC MODELS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; ODDS RATIO; PREDICTIVE VALUE OF TESTS; RETROSPECTIVE STUDIES; RISK ASSESSMENT; RISK FACTORS; SEVERITY OF ILLNESS INDEX; TIME FACTORS; TREATMENT FAILURE;

EID: 84879599097     PISSN: 01726390     EISSN: None     Source Type: Journal    
DOI: 10.5754/hge0851     Document Type: Article

References (30)

1. Barbut F, Corthier G, Charpak Y et al. Prevalence and pathogenicity of Clostridium difficile in hospitalized patients. A French multicenter study. Arch Intern Med 1996; 156: 1449-1454 (Pubitemid 26226940)
2. Bartlett JG. Clinical practice. Antibiotic-associated diarrhea. N Engl J Med 2002; 346: 334-339
3. Pepin J, Valiquette L, Alary ME et al. Clostridium difficile-associated diarrhea in a region of Quebec from 1991 to 2003: a changing pattern of disease severity. CMAJ 2004; 171: 466-472 (Pubitemid 39179608)
4. Redelings MD, Sorvillo F, Mascola L. Increase in Clostridium difficile-related mortality rates, United States, 1999-2004. Emerg Infect Dis 2007; 13:1417-1419 (Pubitemid 47510317)
5. Warny M, Pepin J, Fang A et al. Toxin production by an emerging strain of Clostridium difficile associated with outbreaks of severe disease in North America and Europe. Lancet 2005; 366: 1079-1084 (Pubitemid 41338761)
6. Bartlett JG. The case for vancomycin as the preferred drug for treatment of Clostridium difficile infection. Clin Infect Dis 2008; 46: 1489-1492 (Pubitemid 351706727)
7. McFarland LV. Update on the changing epidemiology of Clostridium difficile-associated disease. Nat Clin Pract Gastroenterol Hepatol 2008; 5: 40-48
8. Teasley DG, Gerding DN, Olson MM et al. Prospective randomised trial of metronidazole versus vancomycin for Clostridium-difficile-associated diarrhoea and colitis. Lancet 1983; 2: 1043-1046 (Pubitemid 14235361)
9. Wenisch C, Parschalk B, Hasenhundl M, Hirschl AM, Graninger W. Comparison of vancomycin, teicoplanin, metronidazole, and fusidic acid for the treatment of Clostridium difficile-associated diarrhea. Clin Infect Dis 1996; 22: 813-818 (Pubitemid 26255600)
10. Pepin J, Alary ME, Valiquette L et al. Increasing risk of relapse after treatment of Clostridium difficile colitis in Quebec, Canada. Clin Infect Dis 2005; 40: 1591-1597 (Pubitemid 40720808)
11. Lagrotteria D, Holmes S, Smieja M, Smaill F, Lee C. Prospective, randomized inpatient study of oral metronidazole versus oral metronidazole and rifampin for treatment of primary episode of Clostridium difficile-associated diarrhea. Clin Infect Dis 2006; 43: 547-552 (Pubitemid 44267111)
12. Tae CH, Jung SA, Song HJ et al. The first case of antibiotic-associated colitis by Clostridium difficile PCR ribotype 027 in Korea. Journal of Korean medical science 2009; 24: 520-524
13. Kim J, Pai H, Seo MR, Kang JO. Epidemiology and clinical characteristics of Clostridium difficile infection in a Korean tertiary hospital. Journal of Korean medical science 2011; 26: 1258-1264
14. Zar FA, Bakkanagari SR, Moorthi KM, Davis MB. A comparison of vancomycin and metronidazole for the treatment of Clostridium difficile-associated diarrhea, stratified by disease severity. Clin Infect Dis 2007; 45: 302-307 (Pubitemid 47101025)
15. Musher DM, Aslam S, Logan N et al. Relatively poor outcome after treatment of Clostridium difficile colitis with metronidazole. Clin Infect Dis 2005; 40: 1586-1590 (Pubitemid 40720807)
16. Pepin J, Valiquette L, Gagnon S, Routhier S, Brazeau I. Outcomes of Clostridium difficile-associated disease treated with metronidazole or vancomycin before and after the emergence of NAP1/027. The American journal of gastroenterology 2007; 102: 2781-2788 (Pubitemid 350179349)
17. Aslam S, Hamill RJ, Musher DM. Treatment of Clostridium difficile-associated disease: old therapies and new strategies. The Lancet infectious diseases 2005; 5: 549-557 (Pubitemid 41196754)
18. Fernandez A, Anand G, Friedenberg F. Factors associated with failure of metronidazole in Clostridium difficile-associated disease. Journal of clinical gastroenterology 2004; 38: 414-418
19. Hu MY, Maroo S, Kyne L et al. A prospective study of risk factors and historical trends in metronidazole failure for Clostridium difficile infection. Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association 2008; 6: 1354-1360
20. Poutanen SM, Simor AE. Clostridium difficile-associated diarrhea in adults. CMAJ 2004; 171: 51-58 (Pubitemid 38925121)
21. Gerding DN. Clindamycin, cephalosporins, fluoroquinolones, and Clostridium difficile-associated diarrhea: this is an antimicrobial resistance problem. Clin Infect Dis 2004; 38: 646-648 (Pubitemid 38333859)
22. Olson MM, Shanholtzer CJ, Lee JT, Jr., Gerding DN. Ten years of prospective Clostridium difficile-associated disease surveillance and treatment at the Minneapolis VA Medical Center, 1982-1991. Infection control and hospital epidemiology : the official journal of the Society of Hospital Epidemiologists of America 1994; 15: 371-381
23. Modena S, Gollamudi S, Friedenberg F. Continuation of antibiotics is associated with failure of metronidazole for Clostridium difficile-associated diarrhea. Journal of clinical gastroenterology 2006; 40: 49-54 (Pubitemid 44378077)
24. Paltansing S, van den Berg RJ, Guseinova RA et al. Characteristics and incidence of Clostridium difficile-associated disease in The Netherlands, 2005. Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and infectious Diseases 2007; 13: 1058-1064
25. Ricciardi R, Rothenberger DA, Madoff RD, Baxter NN. Increasing prevalence and severity of Clostridium difficile colitis in hospitalized patients in the United States. Archives of surgery 2007; 142: 624-631; discussion 631
26. Miller AT, Tabrizian P, Greenstein AJ et al. Long-term follow-up of patients with fulminant Clostridium difficile colitis. Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract 2009; 13: 956-959
27. Gravel D, Miller M, Simor A et al. Health care-associated Clostridium difficile infection in adults admitted to acute care hospitals in Canada: a Canadian Nosocomial Infection Surveillance Program Study. Clin Infect Dis 2009; 48: 568-576
28. Kenneally C, Rosini JM, Skrupky LP et al. Analysis of 30-day mortality for clostridium difficile-associated disease in the ICU setting. Chest 2007; 132: 418-424 (Pubitemid 47282371)
29. Morrison RH, Hall NS, Said M et al. Risk factors associated with complications and mortality in patients with Clostridium difficile infection. Clin Infect Dis 2011; 53: 1173-1178
30. Hardt C, Berns T, Treder W, Dumoulin FL. Univariate and multivariate analysis of risk factors for severe Clostridium difficile-associated diarrhoea: importance of co-morbidity and serum C-reactive protein. World journal of gastroenterology : WJG 2008; 14: 4338-4341.